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Abstract- Emergence and dissemination of carbapenem 
resistance among Enterobacteriaceae represent a significant 
threat to the management of nosocomial infections. Klebsiella 
pneumoniae had proved to be the most concerned as multidrug-
resistant bacteria causing severe infections with limited 
treatment options. In the present study, we investigate the 
molecular epidemiology of 21 ertapenem-resistant strains of 
Klebsiella pneumoniae collected in Rabta hospital of Tunisia, 
between June 2010 and December 2011. The molecular  
epidemiology including the characterization of carbapenemases 
and others β-lactamases, pulsed-field gel electrophoresis, were 
carried out. Medicals records were reviewed to evaluate 
predictive factors for infection. All strains were multidrug 
resistant. The OXA-48 carbapenemase was identified in all 
strains and was associated with CTX-M-15 and CTX-M-
14/CMY-4 in 11 and 1 cases, respectively. Pulsed-field gel 
electrophoresis typing indicated the clonal dissemination of an 
epidemic strain. The risk factors for acquired OXA-48 
infections were: severity of underlying disease, longer length 
hospital stay and admission to an intensive care unit.  
Amplification of antibiotic resistance with expression of 
carbapenemase and extended-spectrum β-lactamase in the 
same strain requires continuous surveillance programs using 
molecular techniques as powerful tools for early detection and 
for prevention of dissemination of these pan-drug-resistant 
isolates. 
 
Index Terms :  Klebsiella pneumoniae, Multidrug resistance, 
carbapenmaes, DNA sequencing, OXA-48, pulsed-field gel 
electrophoresis, extended-spectrum β-lactamase 
I. INTRODUCTION 
Emergence of carbapenamase-producing 
Enterobacteriaceae, is currently a major public health 
concern worldwide [1]. Klebsiella pneumoniae (K. 
pneumoniae) had proved to be the most important 
enterobacterial species as a source of hospital spread of 
multidrug resistance [2].  
The wide spread of this pathogen was related to its 
ability to carry plasmid encoded β-lactamases such as 
extended-spectrum β-lactamase (ESBLs) and 
carbapenemases with others determinants of resistance 
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 [3,4]. A large variety of carbapenemases has been 
identified in K. pneumoniae strains belonging to Ambler 
class A, B or D enzymes [5] which some occurred with 
close geographic associations [6,[7]. In Tunisia, the first 
carbapenemase producer was a VIM-4 metallo-β-
lactamase K. pneumoniae strain, identified in 2006 [8]. 
Since then, many studies have reported the occurrence of 
oxacillinase OXA-48 [9-11]. In this purpose, a prospective 
study was undertaken to investigate the molecular 
epidemiology of 21 ertapenem-resistant strains of K. 
pneumoniae collected in Rabta hospital of Tunisia between 
June 2010 and December 2011 and to evaluate predictive 
factors for infection.   
II. MATERIALS AND METHODS 
A. Bacterial strains 
This retrospective study was performed from June 2010 
to December 2011, 2014 in the Microbiology Laboratory at 
Rabta University Hospital in Tunis (Tunisia). This 
collection consisted of 21 non-replicate carbapenem-
resistant K. pneumoniae strains: 20 strains were recovered 
from invasive clinical specimens, including urine (n=7), 
catheters (n=5), tracheal aspirate (n=3), blood (n=3) and 
wounds (n=2) and one environmental strain recovered 
from an atomizer in Intensive Care Unit (ICU). The strains 
were obtained from patients hospitalized in various wards: 
ICU (ICU1), ICU from general surgery unit (ICU2), 
urology, nephrology, emergency, cardio-vascular surgery 
infectiology unit, general surgery, cardiology and private 
hospital. 
B. Review of medical records 
The medical records of 18 infected patients were 
collected by a prospective chart review including patient’s 
age, sex, length of stay before infection, underlying 
diseases, admission to an intensive care unit, antimicrobial 
treatment during hospitalization and the final outcome of 
infection. 
C. Microbial Identification and antibiotic 
susceptibility testing and phenotypic screening for 
production of carbapenemases 
Isolates were identified by using a Vitek 2 Gram-
negative Identification System (bio-Mérieux, Marcy 
l’Etoile, France).  
Antibiotic susceptibility was tested by disk diffusion 
method (DDM) on Mueller-Hinton (MH) agar plates and 
results were interpreted according to the standards of the 
French Antibiogram Committee (CA-SFM) 
(http://www.sfm.asso.fr) for the following antibiotics: 
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amoxicillin, amoxicillin-clavulanic acid, ticarcillin, 
piperacillin, cephalotin, cefsulodine, cefoxitin, cefotaxime, 
ceftriaxone, ceftazidime, cefepime, imipenem, ertapenem, 
streptomycin, kanamycin, gentamicin, tobramycin, 
amikacin, nalidixic acid, pefloxacin, ofloxacin, 
ciprofloxacin, levofloxacin, colistin, trimethoprim-
sulfamethoxazole, tetracycline and tigecycline. Minimum 
inhibitory concentrations (MICs) of imipenem were 
determined by the E-test strips (bio-Mérieux) and the 
results were interpreted according to the breakpoints 
established by the guidelines of CA-SFM (susceptibility 
was defined by MICs ≤ 2 µg/ml and resistance was 
defined by MICs >8 µg/ml). 
Extended spectrum ß-lactamase (ESBL) was detected by 
a double disk synergy test between amoxicillin-clavulanic 
acid and a third generation cephalosporin. An ertapenem 
disk (10ug, Biorad) was used because of its high sensitivity 
in detecting carbapenemase resistant strains. A reduced 
susceptibility to carbapenems was defined by an inhibition 
diameter around ertapenem disk less than 28 mm. The 
modified Hodge test was utilized for the detection of 
carbapenemase. Escherichia coli (E. coli) ATCC 25922 
was used as reference strain for antimicrobial 
susceptibility testing. 
D. Polymerase Chain Reaction (PCR) amplification 
and DNA sequence analysis of resistance genes 
DNA extraction was performed by an alkaline lysis 
protocol as described previously [12]. The strains were 
screened for the presence of carbapenemase genes 
(bla
KPC
, bla
OXA-48
, bla
IMP and blaVIM),  extended-spectrum 
β-lactamases (blaCTX-M, blaSHV and blaTEM ) and plasmid-
mediated  AmpC cephalosporinases (blaCMY, blaACC and 
blaDHA ) by PCR [5,8,13]. 
PCR products were purified using a purification Kit 
(Promega) according to the manufacturer’s procedure and 
sequenced on an ABI Prism® 3100 DNA sequencer 
(Applied Biosystems, Foster City, CA, USA). The 
nucleotide sequences were analyzed using software 
available at the website of the National Center of 
Biotechnology Information 
(http://www.ncbi.nlm.nhi.gov). 
E. Pulsed-field gel electrophoresis analysis 
All isolates were typed by using pulsed-field gel 
electrophoresis (PFGE) which was performed according to 
a previously described protocol [14]. After digestion with 
XbaI enzyme, the DNA fragments were separated by 
electrophoresis on 1% (w/v) agarose gels and 0.5 Tris-
borate-EDTA buffer using a CHEF DRIII apparatus (Bio-
Rad Laboratories, Inc, Richmond, UA, USA). 
Electrophoresis conditions were 14°C at a gradient of 
6V/cm for 22 h with switch times ranging from 2.2 to 
54.2 seconds of linear ramping. The DNA fingerprints 
generated were analyzed with the fingerprintingTM–II 
Software Version 3.00 (Bio-Rad, Germany). Strains 
showing 85 % or more of similarity were classified as 
genetically related and assigned to the same lineage. 
 
 
III. RESULTS 
A. Risk factors for infection 
Clinical characteristics of infected patients were 
summarized in Table 1. All cases presumed to have been 
acquired during hospitalization. These patients consisted of 
12 males and 6 females with the mean age of 56.1 years. All 
cases had severe underlying disease (renal insufficiency, 
diabetes, pulmonary disease, liver disease, receipt of an 
organ transplantation, trauma, and malignancy) and 
presented a prolonged hospital stay (over 17 days). Six 
patients died after a prolonged hospital stay in intensive care 
unit especially, with severe sepsis. The crude mortality was 
44 % reflecting the critical status of the patients. For 
antimicrobial treatment, a greater proportion of cases was 
exposed to numerous inappropriate antibiotics before the 
onset of infection and then was treated with a combined-
drug regimen including mainly imipenem and colistin. 
B. Antibiotic susceptibility testing 
Antimicrobial susceptibility testing of K. pneumoniae 
strains using the DD method and E-test for MIC 
determination revealed high rates of resistance to many 
drugs. All clinical isolates were resistant to amoxicillin, 
piperacillin, ticarcillin, amoxicillin/clavulanic acid, 
ticarcillin/clavulanic acid, piperacillin/tazobactam and 
ertapenem. Ninety percent of isolates were resistant to 
cefoxitin and to extended-spectrum cephalosporins 
including cefotaxime, ceftazidime, ceftriaxone and 
cefepime. Co-resistance to other antibiotics was frequent 
among these isolates with 100% of resistance to all 
fluoroquinolones tested, kanamycin and tobramycin. 
Streptomycin and amikacin still have activity against 
strains. Resistance rate to gentamicin, tetracycline, 
cotrimoxazole and tigecycline were respectively, 90%, 
75%, 70%, and 45%.  MICs determination revealed that 
65% (n=13) of isolates were characterized as 
intermediate to imipenem (MICs were > 2 µg/ml and ≤ 8 
µg/ml) and 35% were characterized as susceptible. All 
strains remained sensitive to colistin (MICs≤22 µg/ml). 
The environmental strain was resistant to all antibiotics 
tested except streptomycin, amikacin and colistin and 
was characterized as intermediate to imipenem (MIC = 6 
µg/ml). 
C. PCR amplification and DNA sequence 
analysis of resistance genes 
PCR analysis of all K. pneumoniae isolates for relevant 
carbapenem-resistance genes (bla
KPC
, bla
IMP and blaVIM) 
was negative. PCR experiments followed by sequencing 
identified blaOXA-48 gene in all isolates, blaCTX-M-15 in 11 
isolates and blaCTX-M-14 associated with blaCMY-4 in 1 
isolate (Table 2).   
D. Pulsed-field gel electrophoresis (PFGE) 
analysis 
All isolates were assigned to 3 different pulsotypes (A, B 
and C) and the cutt-off value of 87% similarity was 
indicated by a dotted red line in Figure 1. One major PFGE 
type (A) was identified comprising 18 clinical isolates and 
the environmental strain (E1. Two OXA-48-producing K. 
pneumoniae were genetically distinct (pulsotype B and C). 
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All isolates recovered from ICU 1 belonged to a single 
molecular type indicating a clonal dissemination 
(pulsotype A in Figure 1). 
IV. DISCUSSION 
Increased prevalence of carbapenemase producing 
Enterobacteriaceae has been reported in many countries 
over the world, albeit with a great variability in the 
occurrence and distribution among different geographic 
areas [1,6]. 
The oxacillinase OXA-48 was first identified in a 
clinical K. pneumoniae isolate from Turkey in 2001 
[15]. Since then, several others OXA-48-like producers 
have been reported in various enterobacterial species, 
mainly in K. pneumoniae isolates, from countries in the 
Middle East, North Africa and Europe [16].  
OXA-48-producing K. pneumoniae cause serious 
infections which are often difficult to treat because of a 
multidrug resistance [16,17].  
 Fig 1. Dendrogram showing the relatedness of PFGE 
patterns of  OXA-48-producing Klebsiella pneumoniae. 
Legend: a cut-off of 87% similarity (vertical red line) was 
chosen for determination of clonal relatedness. The 
horizontal bar on the top left indicates the percentage 
similarity within the strains. The dendrogram demonstrates 
3 clones (A, B and C).  One major PFGE type (A) was 
identified comprising 18 clinical isolates and the 
environmental strain. All isolates recovered from ICU 1 
belonged to a single pulsotype A. 
Abbreviations: ICU1: intensive care unit 1, ICU2:  ICU 
from general surgery unit (ICU2), E1: environmental strain 
from ICU1 
 
In our study, infections due to OXA-48-producing K. 
pneumoniae affected seriously elderly patients with severe 
underlying diseases after a prolonged hospital stay and 
were associated with a significant mortality. It had been 
reported that combination therapy including a carbapenem 
with another active agent, preferentially an aminoglycoside 
or colistin, may be effective against carbapenemase-
producing Enterobacteriaceae with a MIC value for 
meropenem and imipenem < 8 mg/l [18].  However, in our 
study, combination therapy failed to treat OXA-48 
infections in eight cases. Indeed, published data regarding 
efficacy of carbapenems for treating OXA-48 infections 
remains debatable given that OXA-48-like strains 
producers exhibit variable resistance profiles [16].  
In Tunisia, the OXA-48 β-lactamase has been spreading 
at an alarming rate with a prevalence of 13.7% among 
Klebsiella pneumoniae isolates exhibiting reduced 
susceptibility to extended-spectrum cephalosporins and or 
imipenem  [9]. In our study, all 21 ertapenem-resistant 
strains carried OXA-48 carbapenemase. The large and still 
increasing proportion of OXA-48-producing Klebsiella 
pneumoniae seems to be due to the silent spread of this 
mobile determinant [11,19]. In fact, OXA-48-like producers 
have been reported to be difficult to detect since the 
level of acquired resistance to carbapenems may remain 
quite low [20,21] . Reduced susceptibility to imipenem but 
with the MIC still in susceptible range, as low as 2 
µg/ml using E-test, was observed on 35% of isolates in 
our study. It is noteworthy that OXA-48 enzyme 
hydrolyze penicillins and, at a lower level imipenem, but 
spare extended-spectrum cephalosporin [20]. Multidrug 
resistance in OXA-48-producing strains often results from 
the coproduction of various resistance mechanisms, in 
particular Class A extended-spectrum β-lactamase (most 
often CTX-M-15 or SHV-12) and the narrow-spectrum β-
lactamases making those isolates resistant to all β-
lactams available [16]. In our study, OXA-48 
carbapenemase was associated with TEM-1, SHV-1 and 
CTX-M-15 which was the most common CTX-M 
enzyme in K. pneumoniae isolates in Tunisia [22]. CTX-
M-14 enzyme was rarely identified in nosocomial 
infections in Tunisia, even though it has been reported 
to causing an outbreak and to be associated with OXA-
48/ CMY-4 producers [9]. The OXA-48 β-lactamase 
appear to have a greater ability to spread and cause 
outbreaks [16,17]. So, the incidence of OXA-48-
producing K. pneumoniae, reported in this study, was 
attributed to the clonal dissemination of an epidemic 
strain. Contamination of medical e q u i p m e n t  detected 
in the intensive care unit suggested that a potential 
c o m m o n  environmental source of infection was 
implicated in the spread of this bacterium.  
This study underlines that K. pneumoniae is an 
enterobacterial species prone to cause hospital-based 
outbreak of strains carrying multidrug-resistant genes such 
as carbapenemase and ESBL determinants and highlights 
the importance of continuous surveillance programs using 
molecular techniques as powerful tools for early detection 
and prevention of dissemination of these pan-drug- 
resistant isolates. 
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Table 1. Clinical characteristics of infected patients. 
Patient 
Age (yr) 
gender 
Underlying disease 
Date of 
hospitalizati
on 
Days of 
stay before 
detection 
Clinical status Empirical antibiotic therapy 
Oriented antibiotic 
therapy 
Clinical outcome 
1 76/M Renal insufficiency, diabetes 07/06/2010 4  
Nosocomial pneumonia and 
septicemia 
Amoxicillin-clavulanate 
Imipenem, colistin, 
ofloxacin,vancomycin 
Death related 
(septic shock) 
2 64/M Diabetes 24/06/2010 7  Surgical wound infection 
Amoxicillin-clavulanate, 
metronidazole 
Cefotaxim, amikacin, 
metronidazole 
Recovered 
3 64/M Necroziting fascitis 11/06/2010 48  Septicemia 
Cefotaxim,imipenem, colistin, 
ciprofloxacin 
Imipenem , colistin 
Death related 
(septic shock) 
4 64/F Renal and heart insufficiency, diabetes 21/01/2011 45  
Nosocomial pneumonia, urinary 
infection 
Amoxicillin-clavulanate, 
metronidazole  
Amoxicillin-clavulanate Not Determined 
5 60/M Chronic obstructive pulmonary disease 01/03/2011 25  
Nosocomial pneumonia, 
bloodstream infection 
None Imipenem , colistin Recovered 
6 55/F Septic arthritis 10/06/2011 12  Surgical wound infection 
Amoxicillin-clavulanate, ofloxacin, 
gentamicin 
Piperacillin/tazobactam,  
ciprofloxacin 
Recovered 
7 55/F  Diabetes 15/09/2011 3  Urinary infection  Ciprofloxacin, gentamicin Colistin Recovered 
8 56/M Trauma, diabetes 28/08/2011 22  Nosocomial pneumonia Amoxicillin-clavulanate Imipenem , colistin Recovered 
9 31/M Trauma 10/09/2011 10  Septicemia 
Amoxicillin-clavulanate,  
teicoplanine, piperacillin-tazobactam 
Imipenem , colistin 
Death related 
(septic shock) 
10 41/F Pyelonephritis, diabetes 18/09/2011 15  Catheter-related Infection Cefotaxim, ciprofloxacin Imipenem , teicoplanine Death  
11 68/M Chronic obstructive pulmonary disease 05/10/2011 2   Nosocomial pneumonia None None Transferred 
12 82/M Bladder cancer 25/09/2011 19  
Nosocomial pneumonia + 
Septicemia 
Cefotaxim, gentamicin,  
metronidazole 
Imipenem, gentamicin, 
tigecycline 
Death related 
(septic shock) 
13 49/F Renal insufficiency 18/11/2011 8  
Catheter-related bloodstream 
Infection 
Piperacillin-tazobactam, ofloxacin, 
vancomycin 
Imipenem , colistin 
Death related 
(septic shock) 
14 42/M  Tuberculosis meningoencephalitis 15/11/2011 14  Catheter-related Infection Cefotaxim, metronidazole  Cefotaxim, colistin Recovered 
15 30/M Renal insufficiency Not mentionned Persistent urinary Infection  Cefotaxim,ofloxacin Ertapeneme Recovered 
16 58/M Diabetes 21/11/2011 19  Urinary infection 
Cefotaxim, gentamicin,  
metronidazole 
Piperacillin-tazobactam Recovered 
17 46/F Viral meningoencephalitis 12/12/2011 20  Catheter-related Infection Cefotaxim, teicoplanine  Imipenem , colistin Death  
18 69/M Renal and liver insufficiency 02/12/2011 29   
Catheter-related bloodstream 
Infection 
Piperacillin-tazobactam, ofoxacin 
Imipenem, colistin, 
vancomycin 
Death related 
(septic shock) 
Table 2. Characteristics of  OXA-48-producing Klebsiella pneumoniae strains. 
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LegendTable2: ESBL: Extended Spectrum Beta Lactamase , ICU1: intensive care unit 
1, ICU2:  ICU from general surgery unit (ICU2), E1: environmental strain from ICU1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain 
number 
Date of 
isolation 
Specimen Ward 
 
Phenotype 
 Characterization of β-lactamase genes   MIC IPM 
(µg/ml) 
 
Pulsotype 
OXA-48 CTX-M SHV TEM CMY 
1 10/06/2010 
Tracheal 
aspiration 
ICU 1 ESBL + Amp C OXA-48 CTX-M-15 SHV-1 TEM-1   2 A 
2 30/06/2010 Pus 
Cardio-vascular 
surgery 
Amp C OXA-48 
 
SHV-1     6 A 
3 29/07/2010 Blood ICU 1 ESBL + Amp C OXA-48 CTX-M-15 SHV-1 
  
2 A 
4 07/03/2011 Urine Cardiology Amp C OXA-48 
 
SHV-1 
  
8 A 
5 26/03/2011 Blood ICU 1 Amp C OXA-48 
 
SHV-1 
  
4 A 
E 1 18/04/2011 Atomizer ICU 1 Amp C OXA-48 
    
6 A 
6 19/04/2011 Urine Urology ESBL + Amp C OXA-48 CTX-M-14 SHV-1 
 
CMY-4 1,5 B 
7 22/06/2011 Pus  ICU 2  Amp C OXA-48 
 
SHV-1 
  
4 A 
8 24/07/2011 Urine Emergency Amp C OXA-48 
    
8 A 
9 18/09/2011 Urine Infectiology Unit ESBL + Amp C OXA-48 CTX-M-15 SHV-1 TEM-1   4 A 
10 19/09/2011 Tracheal aspirate ICU 2 ESBL OXA-48 CTX-M-15 
   
0,38 C 
11 19/09/2011 Blood ICU 1 ESBL+ Amp C OXA-48 CTX-M-15   TEM-1   3 A 
12 01/10/2011 Catheter ICU 1 Amp C OXA-48 
 
SHV-1 TEM-1   1,5 A 
13 07/10/2011 Tracheal aspirate ICU 1 ESBL + Amp C OXA-48 CTX-M-15 
   
1 A 
14 14/10/2011 Urine Private hospital ESBL + Amp C OXA-48 CTX-M-15       6 A 
15 25/11/2011 Catheter ICU 1 ESBL + Amp C OXA-48 CTX-M-15 
 
TEM-1   3 A 
16 28/11/2011 Catheter ICU 1 ESBL + Amp C OXA-48 CTX-M-15 
 
TEM-1   3 A 
17 09/12/2011 Urine Nephrology ESBL + Amp C OXA-48 CTX-M-15 
 
TEM-1   2 A 
18 10/12/2011 Urine General surgery ESBL + Amp C OXA-48 CTX-M-15 
 
TEM-1   2 A 
19 31/12/2011 Catheter ICU 1 Amp C OXA-48 
    
6 A 
20 31/12/2011 Catheter ICU 1 Amp C OXA-48         3 A 
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